ArticleFrontiers in endocrinology2025
Association between homocysteine and severe cerebral small vessel disease burden in patients with type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cerebral small vessel disease (CSVD) is one of the common complications in patients with type 2 diabetes mellitus (T2DM). Homocysteine (Hcy), an emerging biomarker, has an unclear relationship with the CSVD burden in T2DM patients. This study aims to investigate the association between Hcy levels and the burden of severe CSVD in diabetic patients. Methods: A total of 236 patients with T2DM were enrolled in this study. Based on the total CSVD burden score, patients were divided into a mild CSVD burden group (score ≤ 2, n=181) and a severe CSVD burden group (score > 2, n=55). Multivariable logistic regression models were used to evaluate the association between Hcy levels and severe CSVD burden in T2DM patients. Restricted cubic spline (RCS) analyses were conducted to explore the nonlinear relationship between Hcy and the risk of severe CSVD burden. Subgroup analyses and interaction tests were performed to assess potential differences across groups. Results: Multivariable logistic regression analysis demonstrated that higher Hcy levels were independently associated with an increased risk of severe CSVD burden (OR = 1.13, 95% CI: 1.04-1.23). RCS analysis indicated a positive linear relationship between Hcy levels and the risk of severe CSVD burden. Subgroup analyses showed that this association remained significant in patients with BMI < 25 kg/m Conclusion: Elevated serum Hcy is independently associated with a higher burden of severe CSVD in patients with T2DM. Monitoring and managing Hcy levels may have potential value for identifying patients at greater risk of CSVD progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.